GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Beijing SL Pharmaceutical Co Ltd (SZSE:002038) » Definitions » Operating Income

Beijing SL Pharmaceutical Co (SZSE:002038) Operating Income : ¥-50.7 Mil (TTM As of Mar. 2025)


View and export this data going back to 2004. Start your Free Trial

What is Beijing SL Pharmaceutical Co Operating Income?

Beijing SL Pharmaceutical Co's Operating Income for the three months ended in Mar. 2025 was ¥15.7 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 was ¥-50.7 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Beijing SL Pharmaceutical Co's Operating Income for the three months ended in Mar. 2025 was ¥15.7 Mil. Beijing SL Pharmaceutical Co's Revenue for the three months ended in Mar. 2025 was ¥168.9 Mil. Therefore, Beijing SL Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2025 was 9.28%.

Warning Sign:

Beijing SL Pharmaceutical Co Ltd operating margin has been in a 5-year decline. The average rate of decline per year is -14.2%.

Beijing SL Pharmaceutical Co's 5-Year average Growth Rate for Operating Margin % was -14.20% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Beijing SL Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2025 was 1.20%. Beijing SL Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 was 3.35%.


Beijing SL Pharmaceutical Co Operating Income Historical Data

The historical data trend for Beijing SL Pharmaceutical Co's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Beijing SL Pharmaceutical Co Operating Income Chart

Beijing SL Pharmaceutical Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 169.40 255.15 182.01 250.14 43.77

Beijing SL Pharmaceutical Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 110.09 21.15 -52.99 -34.48 15.67

Beijing SL Pharmaceutical Co Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-50.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Beijing SL Pharmaceutical Co  (SZSE:002038) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Beijing SL Pharmaceutical Co's annualized ROC % for the quarter that ended in Mar. 2025 is calculated as:

ROC % (Q: Mar. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2024 ) + Invested Capital (Q: Mar. 2025 ))/ count )
=62.684 * ( 1 - 5.01% )/( (4869.886 + 5057.16)/ 2 )
=59.5435316/4963.523
=1.20 %

where

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5979.019 - 216.319 - ( 892.814 - max(0, 289.405 - 2488.839+892.814))
=4869.886

Invested Capital(Q: Mar. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6064.703 - 222.708 - ( 784.835 - max(0, 333.995 - 2561.789+784.835))
=5057.16

Note: The Operating Income data used here is four times the quarterly (Mar. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Beijing SL Pharmaceutical Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2024  Q: Mar. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=62.684/( ( (514.244 + max(1288.15, 0)) + (513.008 + max(1427.736, 0)) )/ 2 )
=62.684/( ( 1802.394 + 1940.744 )/ 2 )
=62.684/1871.569
=3.35 %

where Working Capital is:

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(102.966 + 246.334 + 1228.255) - (216.319 + 0 + 73.086)
=1288.15

Working Capital(Q: Mar. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(100.484 + 403.254 + 1257.993) - (222.708 + 0 + 111.287)
=1427.736

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2025) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Beijing SL Pharmaceutical Co's Operating Margin % for the quarter that ended in Mar. 2025 is calculated as:

Operating Margin %=Operating Income (Q: Mar. 2025 )/Revenue (Q: Mar. 2025 )
=15.671/168.896
=9.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Beijing SL Pharmaceutical Co Operating Income Related Terms

Thank you for viewing the detailed overview of Beijing SL Pharmaceutical Co's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Beijing SL Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No.69 Fu shi Road, No.1 Building, Bitongyuan, Haidian district, Beijing, CHN, 100049
Beijing SL Pharmaceutical Co Ltd is a Chinese biotechnology-pharmaceutical company. It is principally focused on developing and marketing gene engineering drugs. The product portfolio of the company includes drugs for Oncology, Hepatopathy and Senile disease. Its products include Filgrastim, Asparaginase, Dasartinib, Enoxaparin, Naftopidil, Ademetionine, Lenalidomide, and others.
Executives
Liang Shu Jie Secretary, Director
Xu Ming Bo Directors, executives
Yang Zhong Fan Supervisors
Chen Yu Lin Director
Qi Yan Ming Supervisors
Xi Wen Ying Executives
Wu Yan Zhuo Executives
Wang Wen Xin Director
Li Ya Jun Executives
Zhao Xia Securities Affairs Representative
Zhang Chun Lei Supervisors
Wang Yong Bo Directors, executives
Lu An Jing Supervisors
Wei Su Yan Director

Beijing SL Pharmaceutical Co Headlines

No Headlines